According to filings with the U.S. Securities and Exchange Commission, Creative BioTherapeutics is raising $3,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Donald Davidson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Creative BioTherapeutics
Dr. Donald Davidson founded Creative BioTherapeutics to create next generation therapies to treat late stage resistant and metastatic cancers. His approach is radically different from large pharmaceutical and other biotech companies. Dr. Davidson has been researching thrombolytics (blood chemistry) and cancer for over 30 years, with much of that time at a large pharmaceutical company. From his ground breaking research in angiogenesis (starve tumor of blood supply), he has generated several patents, papers and cancer drugs that have been tested in clinical trials. Recent advancements in Dr. Davidsons lab at CBT have led to the discovery of a novel escape route for late stage, metastatic, drug resistant lung, breast, colon and brain cancer tumor cells. From these developments, novel, innovative, first-in-class inhibitors for this resistant, survival pathway have been discovered and created. In addition, this same escape route is essential for virus (COVID-19, Influenza A) entry and replication. Currently, we are testing these inhibitors in anti-cancer and anti-viral assays.

To learn more about Creative BioTherapeutics, visit http://creativebio.tech/

Contact:
Donald Davidson, Chief Executive Officer
224-627-6403
https://www.linkedin.com/in/don-davidson-74947967/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.